ABSTRACT
There are emerging and convincing data that certain cells have a natural propensity to migrate to tumors after systemic inoculation into preclinical models. This homing ability can be exploited for using cells as delivery vehicles for anticancer therapeutic or biological agents, which otherwise have major side effects or short half-life, precluding their systemic administration. Another potential use of tumor-seeking cells could be as stealth vehicles to ferry therapeutic nanomaterials to tumors to facilitate penetration, reduce potential toxicity, reduce potential unwanted immune consequences, and reduce removal by the reticuloendothelial system (RES).
